Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
Fig 6
EGFR phosphorylation is markedly reduced by TKI treatment in cells with two copies of L858R EGFR.
A. Cells were treated with the indicated concentration of gefitinib for 4 h. Protein expression or phosphorylation levels were determined by immunoblotting using anti-phospho-EGFR (Y1068), anti-EGFR, anti-phospho-AKT (Ser473), anti-AKT, and β-actin antibodies. B. Densitometric analysis of phospho-EGFR and EGFR protein was performed by Image J software. The value of pEGFR/EGFR in the non-treated sample lane was defined as 100%. *P<0.05, **P<0.01. C. Cells were treated with the indicated concentration of afatinib or gefitinib for 4 h. Protein expression or phosphorylation levels were determined by immunoblotting using anti-phospho-EGFR (Y1068), anti-EGFR, and β-actin antibodies. D. Densitometric analysis of phospho-EGFR and EGFR protein was performed by Image J software. The value of pEGFR/EGFR in the non-treated sample lane was defined as 100%. Statistical analysis: Bonfferoni correction was performed for multiple comparisons. **P<0.01.